Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.48 |
| ▸ | GRN | P28799 | 2/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7391076 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL16750034 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL23030321 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7367874 | 0.84 | ALDH1A1 (0.57) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL22207963 | 0.84 | ALDH1A1 (0.57) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL22207962 | 0.84 | ALDH1A1 (0.57) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7373627 | 0.84 | ALDH1A1 (0.57) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7639101 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL12837937 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL22383990 | 0.80 | ALDH1A1 (0.41) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110917205-A | Substituted nucleosides, nucleotides and analogs thereof | 詹森生物制药有限公司 | 2020-03-27 | — | — | CN | claimed |
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | claimed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | claimed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | claimed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | claimed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | claimed |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3647319-B1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER SHANGHAI CO LTD (CN) | 2025-04-09 | — | — | EP | disclosed |
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | ALDH1A1 3529/4885MEN1 2000/4885LMNA 3786/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | ALDH1A1 3585/4885MEN1 2509/4885LMNA 4731/4885 |
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | ALDH1A1 943/4885MEN1 829/4885LMNA 931/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | ALDH1A1 3585/4885MEN1 2509/4885LMNA 4731/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | ALDH1A1 943/4885MEN1 829/4885LMNA 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.